公开(公告)号：MX2014004210A

公开(公告)日：2014-05-28

申请号：MX2014004210

申请日：2012-10-10

Applicant: UCB PHARMA SA

Inventor： ATES ALI ,  MONTEL FLORIAN ,  VALADE ANNE ,  LORTHIOIR OLIVER

IPC: C07D401/10 ,  A61K31/444 ,  A61P25/06 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14

Abstract: La presente invención se refiere a derivados de 2-oxo-piperidinilo, procesos para la preparación de estos, composiciones farmacéuticas que los contienen y su uso como farmacéuticos.

公开(公告)号：AU2013251079B2

公开(公告)日：2017-03-23

申请号：AU2013251079

申请日：2013-04-19

Applicant: UCB PHARMA SA

Inventor： MICHEL ANNE ,  DOWNEY PATRICK ,  MONTEL FLORIAN ,  SCHELLER DIETER ,  CHRISTOPHE BERNARD

IPC: A61K31/395 ,  A61K31/4439 ,  A61K31/4523 ,  A61K31/4985 ,  A61P25/16

Abstract: The invention pertains to a method of treating Parkinson's disease (PD) in a mammal, comprising administering a first pharmaceutical agent and a second pharmaceutical agent, wherein the first pharmaceutical agent is an antagonist of the adenosine receptor 2 (A

公开(公告)号：EA025288B1

公开(公告)日：2016-12-30

申请号：EA201400444

申请日：2012-10-10

Applicant: UCB PHARMA SA

Inventor： ATES ALI ,  MONTEL FLORIAN ,  VALADE ANNE ,  LORTHIOIR OLIVIER

IPC: C07D401/10 ,  A61K31/444 ,  A61P25/06 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14

Abstract: Визобретенииописаныпроизводные 2-оксопиперидинила, способыихполучения, содержащиеихфармацевтическиекомпозициии ихприменениев качествелекарственныхсредств.

公开(公告)号：CA2849385A1

公开(公告)日：2013-04-18

申请号：CA2849385

申请日：2012-10-10

Applicant: UCB PHARMA SA

Inventor： ATES ALI ,  MONTEL FLORIAN ,  VALADE ANNE ,  LORTHIOIR OLIVIER

IPC: C07D401/10 ,  A61K31/444 ,  A61P25/06 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14

Abstract: The present invention relates to 2-oxo-piperidinyl derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.

公开(公告)号：ES2627541T3

公开(公告)日：2017-07-28

申请号：ES13718320

申请日：2013-04-19

Applicant: UCB PHARMA SA

Inventor： MICHEL ANNE ,  DOWNEY PATRICK ,  MONTEL FLORIAN ,  SCHELLER DIETER ,  CHRISTOPHE BERNARD

IPC: A61K31/395 ,  A61K31/4439 ,  A61K31/4523 ,  A61K31/4985 ,  A61P25/16

Abstract: Una composición farmacéutica para uso en el tratamiento de la enfermedad de Parkinson (EP) en un mamífero, que comprende un primer agente farmacéutico y un segundo agente farmacéutico, en la que el primer agente farmacéutico es el antagonista de receptor de adenosina 2 (A2A) tozadenant y el segundo agente farmacéutico es el antagonista de receptor de D-aspartato de N-metilo (NMDA) de subtipo NR2B radiprodilo.

公开(公告)号：AU2013251079A1

公开(公告)日：2014-11-06

申请号：AU2013251079

申请日：2013-04-19

Applicant: UCB PHARMA SA

Inventor： MICHEL ANNE ,  DOWNEY PATRICK ,  MONTEL FLORIAN ,  SCHELLER DIETER ,  CHRISTOPHE BERNARD

IPC: A61K31/395 ,  A61K31/4439 ,  A61K31/4523 ,  A61K31/4985 ,  A61P25/16

Abstract: The invention pertains to a method of treating Parkinson's disease (PD) in a mammal, comprising administering a first pharmaceutical agent and a second pharmaceutical agent, wherein the first pharmaceutical agent is an antagonist of the adenosine receptor 2 (A

公开(公告)号：AU2012323038A1

公开(公告)日：2014-05-01

申请号：AU2012323038

申请日：2012-10-10

Applicant: UCB PHARMA SA

Inventor： ATES ALI ,  MONTEL FLORIAN ,  VALADE ANNE ,  LORTHIOIR OLIVIER

IPC: C07D401/10 ,  A61K31/444 ,  A61P25/06 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14

Abstract: The present invention relates to 2-oxo-piperidinyl derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.

公开(公告)号：CA2869216A1

公开(公告)日：2013-10-24

申请号：CA2869216

申请日：2013-04-19

Applicant: UCB PHARMA SA

Inventor： MICHEL ANNE ,  DOWNEY PATRICK ,  MONTEL FLORIAN ,  SCHELLER DIETER ,  CHRISTOPHE BERNARD

IPC: A61K31/395 ,  A61K31/4439 ,  A61K31/4523 ,  A61K31/4985 ,  A61P25/16

Abstract: The invention pertains to a method of treating Parkinson's disease (PD) in a mammal, comprising administering a first pharmaceutical agent and a second pharmaceutical agent, wherein the first pharmaceutical agent is an antagonist of the adenosine receptor 2 (A2A) and the second pharmaceutical agent is an antagonist of the N-methyl-D-aspartate (NMDA) receptor subtype NR2B.